|View printer-friendly version|
|Array BioPharma Announces Changes to Board of Directors|
“As founding members of our Board, we thank Dr. Bullock, Dr. Koch and
Dr. Snitman for their exceptional leadership, expertise and
Dr. Koch added, “I am proud to have founded Array and to have worked with Array’s other Board members over the years. We have established a track record of producing high quality drug candidates, advancing 18 drug candidates into human clinical trials, 10 of which are in Phase 2. Array was built on exceptional science and a culture of inventing great molecules, fueled by the passion and skill which our people demonstrate every day. I am confident that exceptional science will continue to guide us through our evolution, and excited to see the impact our discoveries will have for patients.”
In addition, Dr. Snitman noted, “It is an honor to be an Array founder,
serve on its leadership team and Board, and contribute to its success.
Array’s ability to discover and advance drug candidates that have the
promise to impact millions of patient lives has attracted some of the
most well-respected pharmaceutical company partners in the industry,
And Dr. Bullock said, “It has been a privilege to help Array grow and mature into a fully-integrated biopharmaceutical company. Now with new leadership and the stage set for commercial success, it is time for the Board’s representation to evolve as well.”
The decisions to leave the Board did not arise from any disagreement on any matter relating to the Company’s operations, policies or practices.
Earlier this year, Array appointed two new independent directors to
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer. Array is evolving into a
late-stage development company, with two wholly-owned programs, ARRY-614
and ARRY-520, and three partnered programs, selumetinib partnered with
Array BioPharma Inc.